Tetsushu Onita

Dr. Tetsushu Onita

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
TOTetsushu Onita
Tetsushu Onita
NINoriyuki Ishihara
Noriyuki Ishihara
TYTakahisa Yano
Takahisa Yano
Antimicrobial resistance (AMR) poses a critical global health threat, necessitating the optimal use of existing antibiotics. Pharmacokinetic/pharmacodynamic (PK/PD) principles provide a scientific framework for optimizing antimicrobial therapy, particularly to respond to evolving resistance patterns. This review examines PK/PD strategies for antimicrobial dosing optimization, focusing on three key aspects. First, we discuss the importance of drug concentration management for enhancing efficacy while preventing toxicity, considering various patient populations, including pediatric and elderly patients with their unique physiological characteristics. Second, we analyze different PK modeling approaches: the classic top-down approach exemplified by population PK analysis, the bottom-up approach represented by physiologically based PK modeling, and hybrid models combining both approaches for enhanced predictive performance. Third, we explore clinical applications, including nomogram-based dosing strategies, Bayesian estimation, and emerging artificial intelligence applications, for real-time dose optimization. Critical challenges in implementing PK/PD simulation are addressed, particularly the selection of appropriate PK models, the optimization of PK/PD indices, and considerations concerning antimicrobial concentrations at infection sites. Understanding these principles and challenges is crucial for optimizing antimicrobial therapy and combating AMR through improved dosing strategies.

12 December 2020 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
TOTetsushu Onita
Tetsushu Onita
KIKazuro Ikawa
Kazuro Ikawa
KNKogenta Nakamura
Kogenta Nakamura
GNGenya Nishikawa
Genya Nishikawa
IKIkuo Kobayashi
Ikuo Kobayashi
NMNorifumi Morikawa
Norifumi Morikawa

2 February 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
TOTetsushu Onita
Tetsushu Onita
KIKazuro Ikawa
Kazuro Ikawa
NINoriyuki Ishihara
Noriyuki Ishihara
HTHiroki Tamaki
Hiroki Tamaki
TYTakahisa Yano
Takahisa Yano
NMNorifumi Morikawa
Norifumi Morikawa
This study aimed to assess the dosing regimens of ampicillin/sulbactam for pneumonia based on pulmonary pharmacokinetic (PK)/pharmacodynamic (PD) target attainment. Using the literature data, we developed pulmonary PK models and estimated the probabilities of attaining PK/PD targets in lung tissue. Against bacteria other than A. baumannii (the general treatment), the PK/PD target was set as both 50% time above the minimum inhibitory concentration (T > MIC) for ampicillin and 50% T > 0.5 MIC for sulbactam. For the A. baumannii treatment, the PK/PD target was set as 60% T > MIC for sulbactam. The pulmonary PK/PD breakpoint was defined as the highest minimum inhibitory concentration (MIC) at which the target attainment probability in the lung tissue was ≥90%. The lung tissue/serum area under the drug concentration–time curve from 0 to 3 h (AUC0–3h) ratios for ampicillin and sulbactam were 0.881 and 0.368, respectively. The ampicillin/sulbactam AUC0–3h ratio in the lung tissue was 3.89. For the general treatment, the pulmonary PK/PD breakpoint for ampicillin/sulbactam at 3 g four times daily in typical patients with creatinine clearance (CLcr) of 60 mL/min was 2 μg/mL, which covered the MIC90s (the MICs that inhibited the growth of 90% of the strains) of most gram-positive and gram-negative bacteria. For the A. baumannii treatment, the pulmonary PK/PD breakpoint for ampicillin/sulbactam at 9 g 4-h infusion three times daily (27 g/day) in patients with a CLcr of 60 mL/min was 4 μg/mL, which covered the MIC90 of A. baumannii. A PK/PD evaluation for pneumonia should be performed in the lung tissue (the target site) rather than in the blood because sulbactam concentrations are lower in lung tissue. These findings should facilitate the selection of ampicillin/sulbactam regimens for pneumonia caused by various bacteria, including A. baumannii.

1 February 2020 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KNKogenta Nakamura
Kogenta Nakamura
KIKazuro Ikawa
Kazuro Ikawa
GNGenya Nishikawa
Genya Nishikawa
IKIkuo Kobayashi
Ikuo Kobayashi
MTMotoi Tobiume
Motoi Tobiume
NMNorifumi Morikawa
Norifumi Morikawa

27 July 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
TOTetsushu Onita
Tetsushu Onita
NINoriyuki Ishihara
Noriyuki Ishihara
AIAmika Ikebuchi
Amika Ikebuchi
TYTakahisa Yano
Takahisa Yano
NNNobuhiro Nishimura
Nobuhiro Nishimura
KNKohji Naora
Kohji Naora

22 February 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
TOTetsushu Onita
Tetsushu Onita
KIKazuro Ikawa
Kazuro Ikawa
NINoriyuki Ishihara
Noriyuki Ishihara
HTHiroki Tamaki
Hiroki Tamaki
TYTakahisa Yano
Takahisa Yano
NMNorifumi Morikawa
Norifumi Morikawa
Background: We aimed to develop population pharmacokinetic (PK) models of ampicillin and sulbactam using pooled data analysis and to optimize dosing regimens of ampicillin-sulbactam (combination ratio of 2:1) in pediatric patients. Methods: Population PK models of ampicillin and sulbactam were separately developed by simultaneously fitting plasma and urine data from pediatric patients in 14 published studies. Based on these models, we estimated the probability of attaining a pharmacodynamic (PD) target [50% of time that free drug concentrations above the minimum inhibitory concentration, 50% fT > minimum inhibitory concentration (MIC)] against MIC90 [MIC that blocked the growth of 90% of the strains] of common bacteria in community-acquired pneumonia. Results: The analysis included 54 pediatric patients (0.083–16.42 years of age, 4.0–77.0 kg of body weight). A total of 284 plasma concentrations and 90 urinary excretions from 0 to 6 hours after administration were used for population PK modeling. The data were adequately described by 2-compartment models for ampicillin and sulbactam. Age was not a statistically significant covariate in the PK of either drug. The PK/PD breakpoint MICs for 45 mg/kg 3 times daily and 75 mg/kg 4 times daily (q.i.d.) were 0.25 and 1 μg/mL, respectively. For empiric therapy of community-acquired pneumonia, because MIC90 values for the main target pathogens is high (MIC90 = 2 μg/mL for Streptococcus pneumoniae and MIC90 = 4 μg/mL for Haemophilus influenzae), 75 mg/kg q.i.d. (Food and Drug Administration–approved maximum dosage in United States) might be better than 45 mg/kg 3 times daily (within approved dosage in Japan) to cover many pathogens. Conclusions: From the results of this PK/PD approach, 75 mg/kg q.i.d. (Food and Drug Administration–approved maximum dosage) should be recommended in the empiric therapy of community-acquired pneumonia.